logo

Sangamo Biosciences Inc (SGMO)



Trade SGMO now with
  Date
  Headline
1/3/2018 7:33:16 AM Sangamo Therapeutics, Pfizer To Collaborate For Development Of Zinc Finger Protein Gene Therapy For ALS
11/15/2017 5:22:50 PM Wedbush Is Raising Sangamo Biosciences Inc (SGMO) FY18 Rev. Estimate To 28.7 M From 16.3 M
11/15/2017 5:22:35 PM Wedbush Is Increasing Sangamo Biosciences Inc (SGMO) Q4 18 Rev. Estimate To 11.1 M From 4.9 M
11/15/2017 5:22:14 PM Wedbush Is Raising Sangamo Biosciences Inc (SGMO) Q3 18 Rev. Estimate To 10.8 M From 4.6 M
11/15/2017 5:21:56 PM Wedbush Is Increasing Sangamo Biosciences Inc (SGMO) FY17 Rev. Estimate To 38.2 M From 36.4 M
11/15/2017 5:21:43 PM Wedbush Is Raising Sangamo Biosciences Inc (SGMO) Q4 17 Rev. Estimate To 14.7 M From 13.5 M
11/15/2017 5:20:30 PM Wedbush Is Raising Sangamo Biosciences Inc (SGMO) FY18 Estimate To -0.82 From -0.99
11/15/2017 5:20:16 PM Wedbush Is Raising Sangamo Biosciences Inc (SGMO) Q4 18 Estimate To -0.16 From -0.24
11/15/2017 5:19:54 PM Wedbush Is Increasing Sangamo Biosciences Inc (SGMO) Q3 18 Estimate To -0.16 From -0.24
11/15/2017 5:19:32 PM Wedbush Is Increasing Sangamo Biosciences Inc (SGMO) FY17 Estimate To -0.65 From -0.86
11/15/2017 5:19:08 PM Wedbush Is Increasing Sangamo Biosciences Inc (SGMO) Q4 17 Estimate To -0.11 From -0.25
11/15/2017 5:18:38 PM Wedbush Reiterates Sangamo Biosciences Inc (SGMO) At Neutral With $6 Price Target
11/15/2017 1:15:47 AM Sangamo Reports Treatment Of First Patient In Landmark Phase 1/2 Trial Evaluating In Vivo Genome Editing For MPS II
10/2/2017 7:34:03 AM Sangamo And Bioverativ Announce FDA Acceptance Of IND Application For ST-400
8/25/2017 8:02:33 AM Sangam, Pfizer: First Patient Gets Treatment In Phase 1/2 Trial Evaluating SB-525 Gene Therapy For Hemophilia A